English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, December 22, 2016
Eisai and Keio University to Establish a New Industry-Academia Collaboration Site
Tuesday, December 20, 2016
Anticancer Agent Treakisym Approved in Japan for Additional Indication as First-Line Treatment for Low-Grade B-Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Wednesday, November 30, 2016
エーザイ、第39回サンアントニオ乳がんシンポジウムでエリブリンに関する最新データを発表
エーザイ、第70回米国てんかん学会議にてペランパネルおよびルフィナミドに関する最新データを発表
Friday, November 18, 2016
エーザイ、早期アルツハイマー病を対象としたBACE阻害剤「E2609」の開発について
U.S. FDA Grants Fast Track Designation for the Development of Eisai's Bace Inhibitor E2609 for Early Alzheimer's Disease
Monday, November 14, 2016
エーザイ、2016年 医薬品アクセス貢献度調査(ATMインデックス)の結果について
Friday, November 4, 2016
U.K. NICE Recommends Anticancer Agent Halaven as Treatment for Advanced Breast Cancer
エーザイ、英国NICEが抗がん剤「ハラヴェン」を進行性乳がん治療薬として推奨
Monday, October 31, 2016
Enrollment Commences in Phase III Clinical Study of Eisai's BACE Inhibitor E2609 in Early Alzheimer's Disease

Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8400